



Session	Emerging Innovative Technologies: Novel Fermentation and Downstream Processing Innovations
Title	Cell-free synthesis of bioactive glycans
Company	eversyn GmbH
Speaker	Dr. Thomas Rexer
Keywords feedstock (max 2)	various
Keywords technology (max 2)	Cell-free synthesis
Keywords End-Product (max 2)	Complex glycans
Abstract:	
eversyn is a biotechnology start-up that emerged as a spin-off from Germany's Max Planck Society with a mission to make essential sugar molecules called glycans accessible and affordable for health and industrial applications. Think of complex glycans as the "molecular handshakes" that cells use to communicate. These complex structures are crucial for human life, influencing, for example, our gut health, yet have remained expensive and difficult to produce. ever syn's breakthrough cell-free enzymatic platform bypasses traditional limitations of cell factories, while enabling flexible, sustainable production. eversyn has successfully launched its first products for R&D applications, with complex glycans in the pipeline for health and infant nutrition applications, alongside a platform technology for modifying therapeutic glycoproteins. For the latter, glycans are particularly critical: over 70% of licensed biopharmaceuticals are glycoproteins, and glycosylation significantly influences blood clearance, therapeutic efficacy, and protein stability. Since 2022, ever syn has secured a total of €2.1 million in funding, including a seed round. Strategic partnerships with industry leaders and emergence from Europe's premier research organization demonstrate our scientific rigor and commercial potential, positioning ever syn to capture significant market share in the rapidly growing nutrition and biopharmaceutical markets.	